Related Experiment Videos
Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline
W Nürnberg1, J Grabbe, B M Czarnetzki
1Department of Dermatology, University Clinics Rudolf Virchow, FU-Berlin, Germany.
Acta Dermato-Venereologica
|January 1, 1995
Summary
This case study explores a novel treatment for refractory idiopathic hypocomplementemic urticarial vasculitis syndrome. A combination therapy of dapsone and pentoxifylline achieved complete remission in a long-standing, treatment-resistant case.
Area of Science:
- Rheumatology
- Dermatology
- Immunology
Background:
- Idiopathic hypocomplementemic urticarial vasculitis syndrome (IHUVSS) is a rare autoimmune condition characterized by chronic urticarial lesions and vasculitis.
- Treatment-resistant cases of IHUVSS pose a significant clinical challenge, often requiring high-dose corticosteroids or immunosuppressants with considerable side effects.
Observation:
- A 40-year-old female patient presented with a 16-year history of IHUVSS refractory to multiple therapies including antihistamines, indomethacin, dapsone, and interferon alpha.
- Initial response to high-dose prednisolone (>25 mg/day) was noted, but monotherapy with pentoxifylline provided only minimal benefit.
Findings:
- A combination regimen of dapsone (100 mg/day) and pentoxifylline (1,200 mg/day) was initiated.
- This dual therapy led to a gradual clinical improvement, achieving complete remission of IHUVSS symptoms within 8 weeks.
- Symptomatic control was sustained for 18 months with no significant adverse events.
Implications:
- Combination therapy with dapsone and pentoxifylline represents a promising, well-tolerated treatment option for severe, therapy-resistant IHUVSS.
- This approach may offer an alternative to long-term high-dose corticosteroid use, potentially reducing associated morbidity.
- Further investigation into this therapeutic strategy is warranted for similar challenging autoimmune vasculitic conditions.